Abstract
Background. We previously found that a decrease in the number of NKT cells and activated CD 25+ peripheral blood lymphocytes (PBLs) before neoadjuvant chemotherapy was associated with an increased likelihood of disease progression in patients with locally advanced triple-negative breast cancer (TN BC).The purpose of this study was to determine the relationship between the initial number of NKT-and CD 25+ PBLs and relapsefree survival (RFS)/overall survival (OS ) in patients with TN BC who received neoadjuvant chemotherapy with cisplatin and paclitaxel followed by surgery.Material and Methods. The study included patients with stage II and III TN BC. The follow-up time was 36 and 66.9 months. Immediately before chemotherapy, the percentage of CD 3+CD 16+CD 56+ (NKT) -, CD 25+- and CD 8+ PBLs was determined by flow cytometry. Statistical analysis of the data was carried out using the Statistics 7 software package. The Kaplan-Meier method was used to determine the relationship between immunological parameters and RFS/ OS .Results. The decreased level of NKT cells before treatment was associated with a decrease in the 3-year RFS [Me: 20.1 (0.533 and 39.7) months] compared to that observed in patients with higher percentage of these cells than in the control (Me was not achieved). There were no statistically significant differences in the 3-year OS between the groups. The initially reduced number of CD 25+ lymphocytes in comparison with the control was associated with decreased rates of both RFS and OS . The difference in DFS and OS was more significant between the groups of patients who simultaneously had an increased initial number of both NKT and CD 25+ cells and patients in whom both cell populations were below normal levels.Conclusion. The initial (prior to chemotherapy) number of NKT and activated CD 25+ PBLs can apparently be a predictive factor in TN BC patients, who received neoadjuvant chemotherapy with cisplatin and paclitaxel.
Highlights
We previously found that a decrease in the number of NKT cells and activated CD25+ peripheral blood lymphocytes (PBLs) before neoadjuvant chemotherapy was associated with an increased likelihood of disease progression in patients with locally advanced triple-negative breast cancer (TN BC)
The purpose of this study was to determine the relationship between the initial number of NKT-and CD25+ PBLs and relapsefree survival (RFS)/overall survival (OS) in patients with TN BC who received neoadjuvant chemotherapy with cisplatin and paclitaxel followed by surgery
Before chemotherapy, the percentage of CD3+CD16+CD56+ (NKT), CD25+- and CD8+ PBLs was determined by flow cytometry
Summary
Заботина Татьяна Николаевна, доктор биологических наук, заведующая отделом клинико-лабораторной диагностики, НИИ КО им. акад. Трапезникова, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Кадагидзе Заира Григорьевна, доктор медицинских наук, профессор, ведущий научный сотрудник, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Шоуа Эсма Константиновна, врач-онколог, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Гордеева Ольга Олеговна, врач-онколог, онкологическое отделение лекарственных методов лечения (химиотерапевтическое) No 3, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Колядина Ирина Владимировна, доктор медицинских наук, профессор кафедры онкологии и паллиативной медицины, РМАНПО Жукова Людмила Григорьевна, доктор медицинских наук, профессор РАН, руководитель отделения химиотерапии ГБУЗ МКНЦ им. Ганьшина Инна Петровна, кандидат медицинских наук, ведущий научный сотрудник, онкологическое отделение лекарственных методов лечения (химиотерапевтическое) No 3, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Мещеряков Андрей Альбертович, доктор медицинских наук, заведующий отделением, онкологическое отделение лекарственных методов лечения (химиотерапевтическое) No 3, ФГБУ «Национальный медицинский исследовательский центр онкологии им.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
